Sol-gel (SLGL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.8M

Revenue (quarter)

$591,000.00

Revenue growth (year over year)

−96.58%

Gross profit (trailing twelve months)

$1.8M

Gross margin

100.00%

Net income (trailing twelve months)

−$16.3M

Net income (quarter)

−$3.7M

Net income growth (year over year)

−131.71%

Net margin

−910.14%

Return on equity

−40.85%

EPS (trailing twelve months)

−$5.62

Book value per share

$14.69

P/E (trailing twelve months)

—

Price to book

4.79

Debt to assets

10.53%

Payout ratio

—

Dividend yield

—

Company profile

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

• Is Sol-gel (SLGL) profitable?

  No. Sol-gel reported a net loss of $16.3M over the trailing twelve months.

• How much revenue does Sol-gel (SLGL) make?

  Sol-gel generated $1.8M in revenue over the trailing twelve months, down 96.58% year over year.

• How do I buy stock in Sol-gel (SLGL)?

  SLGL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.